mTOR: A double-edged sword for diabetes.

Area of Science:

• Endocrinology
• Immunology
• Metabolic signaling

Background:

• Diabetes mellitus is a complex disorder with both metabolic and immune system components.
• The serine-threonine protein kinase, mammalian target of rapamycin (mTOR), is a critical regulator of cellular signaling pathways.
• mTOR influences fuel metabolism and cell function in pancreatic islet beta cells and immune cells.

Purpose of the Study:

• To review the multifaceted roles of mTOR signaling in pancreatic beta cells and immune cells.
• To explore the implications of mTOR signaling in the pathogenesis of diabetes.
• To discuss the potential of targeting mTOR for diabetes treatment.

Main Methods:

• Literature review focusing on mTOR signaling pathways.
• Analysis of the interplay between mTOR, fuel metabolism, and immune cell function.
• Examination of mTOR's dual effects on pancreatic beta cell function and survival.

Main Results:

• mTOR activation in beta cells can promote growth and proliferation, potentially counteracting diabetes-related insulin secretion defects.
• mTOR signaling in immune cells can alter their metabolism, exacerbating beta cell dysfunction and contributing to diabetes development.
• mTOR exhibits both protective and detrimental effects in the context of diabetes.

Conclusions:

• mTOR signaling is a key mediator linking metabolic and immune dysregulation in diabetes.
• Understanding mTOR's complex roles is crucial for developing effective diabetes therapies.
• Targeting mTOR pathways may offer novel therapeutic strategies for managing diabetes.